Render Target: STATIC
Render Timestamp: 2024-11-22T11:39:04.966Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 01:55:30.510
Product last modified at: 2024-09-30T08:01:21.685Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77

TrkB (80G2) Rabbit mAb #4607

Filter:
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 140
    Source/Isotype Rabbit IgG
    Application Key:
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Immunohistochemistry (Paraffin) 1:2560

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    TrkB (80G2) Rabbit mAb detects endogenous levels of total TrkB protein. The antibody does not cross-react with TrkA.

    Species Reactivity:

    Human

    The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.

    Species predicted to react based on 100% sequence homology:

    Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide surrounding Pro50 of human TrkB.

    Background

    The family of Trk receptor tyrosine kinases consists of TrkA, TrkB, and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3 (1). Neurotrophin signaling through these receptors regulates a number of physiological processes, such as cell survival, proliferation, neural development, and axon and dendrite growth and patterning (1). In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity. TrkA regulates proliferation and is important for development and maturation of the nervous system (2). Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade (3,4). Residues Tyr674/675 lie within the catalytic domain, and phosphorylation at these sites reflects TrkA kinase activity (3-6). Point mutations, deletions, and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA (7-10). TrkA is activated in many malignancies including breast, ovarian, prostate, and thyroid carcinomas (8-13). Research studies suggest that expression of TrkA in neuroblastomas may be a good prognostic marker as TrkA signals growth arrest and differentiation of cells originating from the neural crest (10).
    The phosphorylation sites are conserved between TrkA and TrkB: Tyr490 of TrkA corresponds to Tyr512 in TrkB, and Tyr674/675 of TrkA to Tyr706/707 in TrkB of the human sequence (14). TrkB is overexpressed in tumors, such as neuroblastoma, prostate adenocarcinoma, and pancreatic ductal adenocarcinoma (15). Research studies have shown that in neuroblastomas, overexpression of TrkB correlates with an unfavorable disease outcome when autocrine loops signaling tumor survival are potentiated by additional overexpression of brain-derived neurotrophic factor (BDNF) (16-18). An alternatively spliced truncated TrkB isoform lacking the kinase domain is overexpressed in Wilms’ tumors and this isoform may act as a dominant-negative regulator of TrkB signaling (17).
    1. Huang, E.J. and Reichardt, L.F. (2003) Annu Rev Biochem 72, 609-42.
    2. Segal, R.A. and Greenberg, M.E. (1996) Annu Rev Neurosci 19, 463-89.
    3. Stephens, R.M. et al. (1994) Neuron 12, 691-705.
    4. Marsh, H.N. et al. (2003) J Cell Biol 163, 999-1010.
    5. Obermeier, A. et al. (1993) EMBO J 12, 933-41.
    6. Obermeier, A. et al. (1994) EMBO J 13, 1585-90.
    7. Arevalo, J.C. et al. (2001) Oncogene 20, 1229-34.
    8. Reuther, G.W. et al. (2000) Mol Cell Biol 20, 8655-66.
    9. Greco, A. et al. (1997) Genes Chromosomes Cancer 19, 112-23.
    10. Pierotti, M.A. and Greco, A. (2006) Cancer Lett 232, 90-8.
    11. Lagadec, C. et al. (2009) Oncogene 28, 1960-70.
    12. Greco, A. et al. (2010) Mol Cell Endocrinol 321, 44-9.
    13. Ødegaard, E. et al. (2007) Hum Pathol 38, 140-6.
    14. Huang, E.J. and Reichardt, L.F. (2003) Annu. Rev. Biochem. 72, 609-642.
    15. Geiger, T.R. and Peeper, D.S. (2005) Cancer Res 65, 7033-6.
    16. Han, L. et al. (2007) Med Hypotheses 68, 407-9.
    17. Aoyama, M. et al. (2001) Cancer Lett 164, 51-60.
    18. Desmet, C.J. and Peeper, D.S. (2006) Cell Mol Life Sci 63, 755-9.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.